Plain-English translation of NCT05440422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help protect the heart and blood vessels in people with lupus. People with lupus have higher risk of heart disease, and this study wants to see if can reduce inflammation in blood vessels and improve how well they work. Researchers will measure changes in blood vessel function and inflammation markers to understand if this treatment helps.
People with lupus face a higher risk of heart disease and clogged arteries at a younger age than the general population. This trial exists to see if this medication can reduce the inflammation in blood vessels that contributes to heart disease, potentially offering patients a new way to protect their long-term heart health.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either or a placebo (a non-active treatment that looks identical) while your lupus medications stay the same. Over 28 weeks, you will have study visits where doctors will measure your blood vessel function using special scans and tests, take blood samples to check biomarkers, and monitor you for any side effects. You will need to keep taking your regular lupus medications unchanged during the study and agree not to change your blood pressure, diabetes, or cholesterol medications.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States